Alvotech jumps after Barclays upgrade and doubled FDA optimism
Alvotech (ALVO) rose about 8% intraday in U.S. trading after Barclays flipped its rating and doubled its price target, saying it is optimistic about FDA approving three biosimilar programs.
Shares of Alvotech (ALVO) rose about 8% intraday in U.S. trading on Wednesday after Barclays changed its view on the Icelandic biosimilar maker and doubled its price target, while saying it was more optimistic the U.S. Food and Drug Administration (FDA) will approve three of the company’s biosimilar programs.